Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246517 | 0.85 | SLC6A4 (0.59) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6246514 | 0.85 | SLC6A4 (0.59) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6246512 | 0.85 | SLC6A4 (0.59) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6246873 | 0.84 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6246875 | 0.84 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6246871 | 0.84 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13409766 | 0.79 | NPC1 (0.53) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3363454 | 0.79 | NPC1 (0.53) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10995616 | 0.78 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11133547 | 0.78 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-20160235856-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LIMITED (CY) | 2016-08-18 | — | — | US | disclosed |
| US-9193969-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2015-11-24 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2012-12-20 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | ZALICUS INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | ZALICUS INC. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SLC6A2 71/4885SLC6A4 34/4885SLC6A3 226/4885 |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A2 3501/4885SLC6A4 4537/4885SLC6A3 4289/4885 |
| US-20160235856-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | SLC6A2, SLC18A2, SLC1A1 | SLC6A2 1/4885SLC6A4 8/4885SLC6A3 6/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | SLC6A2 4758/4885SLC6A4 4825/4885SLC6A3 4742/4885 |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | METTL16, SYNCRIP, FBL | SLC6A2 3147/4885SLC6A4 3126/4885SLC6A3 4037/4885 |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | S100B, S100P, S100A6 | SLC6A2 1042/4885SLC6A4 761/4885SLC6A3 3786/4885 |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | IFNG, IL5, HAVCR2 | SLC6A2 4415/4885SLC6A4 4506/4885SLC6A3 4759/4885 |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | SLC6A2, SLC18A2, SLC1A1 | SLC6A2 1/4885SLC6A4 8/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.